Faeth CFO reports stock option holdings
Faeth Therapeutics, Inc. filed an initial ownership report for its Chief Financial Officer, Brian C. Stephenson, showing a stock option to purchase common stock.
Rhea-AI Filing Summary
Faeth Therapeutics, Inc. filed an initial ownership report for its Chief Financial Officer, Brian C. Stephenson, showing a stock option to purchase common stock. The option covers 166,435 underlying shares at an exercise price of $29.37 per share and expires on March 10, 2036.
According to the vesting terms, 25% of the shares subject to the option vest and become exercisable on March 11, 2027. The remaining shares vest in 36 equal monthly installments thereafter, so the option is fully vested by March 11, 2030, subject to his continuous service with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
STEPHENSON BRIAN C
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 166,435 contracts (Direct)
Footnotes (1)
- F1. 25% of the shares subject to the option vest and become exercisable on March 11, 2027, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the vesting commencement date, or March 11, 2030, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Key Figures
Underlying shares: 166,435 shares
Exercise price: $29.37 per share
Initial vesting date: March 11, 2027
+2 more
5 metrics
Underlying shares
166,435 shares
Underlying common stock for CFO stock option
Exercise price
$29.37 per share
Stock option exercise price
Initial vesting date
March 11, 2027
25% of option vests
Full vesting date
March 11, 2030
Option fully vested, subject to continuous service
Expiration date
March 10, 2036
Option expiration
Key Terms
Stock Option (right to buy), exercise price, vesting, expiration date
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"exercisePrice: 29.3700"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"25% of the shares subject to the option vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-03-10T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider position is reported for Faeth Therapeutics (FTH) in this Form 3?
The filing reports that Brian C. Stephenson, Chief Financial Officer of Faeth Therapeutics, holds a stock option. This option gives him rights over 166,435 shares of common stock, reflecting his initial derivative equity position as an officer of the company.
What is the exercise price of the reported Faeth Therapeutics (FTH) stock option?
The exercise price of Brian Stephenson’s stock option is $29.37 per share. This is the fixed price at which he can purchase Faeth Therapeutics common stock once the option vests and becomes exercisable under the stated vesting schedule.
When does Brian Stephenson’s Faeth Therapeutics (FTH) option begin vesting and fully vest?
Twenty-five percent of the option vests and becomes exercisable on March 11, 2027. The remaining shares vest in 36 equal monthly installments, so the option is fully vested by March 11, 2030, assuming continued service with Faeth Therapeutics.
When does the reported Faeth Therapeutics (FTH) stock option held by the CFO expire?
The stock option held by Brian Stephenson expires on March 10, 2036. After this expiration date, any unexercised portion of the option can no longer be used to purchase Faeth Therapeutics common stock under the terms described.
AI-generated analysis. How Rhea-AI works. Not financial advice.
